# Pulmonary Nodule Follow-Up Thresholds

Choose the management pathway before applying a size cutoff: Fleischner thresholds apply to incidental CT nodules, whereas Lung-RADS governs screening findings. Nodule attenuation, size, multiplicity, prior stability, growth, and pretest malignancy probability determine surveillance, PET/CT, tissue sampling, or surgical diagnosis.

**Clinical question:** Which pulmonary nodules require no follow-up, CT surveillance, PET/CT, biopsy, or surgical diagnosis?

Updated: 2026-09-15T18:15:05.458255+00:00

## What matters in practice
- First classify the detection context: Fleischner recommendations apply to incidentally detected nodules, while Lung-RADS is specific to lung cancer screening examinations.[2][19]
- For incidental solid nodules, a 6 mm threshold separates most nodules needing no routine follow-up from those requiring interval CT; management then varies with patient risk, multiplicity, and size.[19][23]
- For a solid nodule larger than 8 mm, choose 3-month CT, PET/CT, or tissue sampling according to malignancy probability and procedural fitness rather than size alone.[8][19][23]
- Persistent subsolid nodules warrant a different pathway from solid nodules because pure ground-glass and part-solid morphology carry distinct biologic behavior and surveillance needs.[16][19]
- Retrieve prior imaging before ordering new testing: documented stability and absence of growth can avert invasive evaluation, whereas growth substantially increases concern for malignancy.[9][10]

## Use Fleischner for incidental nodules and Lung-RADS for screening CT

Do not apply screening categories to a nodule found incidentally on diagnostic CT.

Determine whether the nodule was detected on an incidental CT or within a formal low-dose CT screening program. Fleischner 2017 guidance addresses incidentally discovered nodules and deliberately distinguishes this population from screening cohorts, whereas Lung-RADS was created for individuals undergoing lung cancer screening.[1][19]

Before assigning a follow-up interval, review all available prior chest CT, CT angiography, cardiac CT, and upper-abdominal CT images. Growth on serial imaging shifts management toward malignancy evaluation; a calcified nodule with an organized central, laminated, or popcorn pattern that remains static for more than 2 years is generally considered benign.[9][10]

Request thin-section CT characterization when attenuation is uncertain. A lesion that appears pure ground glass on 5-mm sections may prove solid or calcified on 1-mm reconstructions, which changes the applicable threshold and surveillance pathway.[20]
- Document maximum diameter, solid versus pure ground-glass versus part-solid attenuation, number of nodules, location, margin morphology, and any measurable solid component before selecting a pathway.[11][19]
- Incorporate patient-level risk into incidental-nodule decisions, including tobacco exposure and other clinical risk factors; Fleischner follow-up recommendations vary by low- versus high-risk status.[5][19][23]
- For a screening CT reported with Lung-RADS, follow the assigned category and obtain comparison imaging before final classification when prior complete lung imaging exists.[23]

*Detection context determines which reporting and follow-up framework applies.[2][19][23]*

| Clinical context | Primary framework | Immediate action |
| --- | --- | --- |
| Nodule found incidentally on diagnostic chest, cardiac, abdominal, trauma, or angiographic CT | Fleischner incidental-nodule guidance.[19] | Characterize on thin-section CT, compare prior imaging, then apply morphology, size, multiplicity, and patient-risk thresholds.[19][20] |
| Nodule found during an established low-dose CT lung cancer screening program | Lung-RADS.[1][23] | Use the Lung-RADS category-specific interval; obtain and compare prior imaging when needed before final classification.[23] |

## Apply 6 mm and 8 mm thresholds to incidental solid nodules

Size directs surveillance intensity, but malignancy probability directs PET/CT, biopsy, or resection.

For a solitary incidental solid nodule smaller than 6 mm, no routine CT follow-up is recommended in a low-risk patient; in a high-risk patient, CT at 12 months is optional. This threshold reflects the low estimated cancer risk for nodules below 6 mm, generally less than 1%.[9][23]

For a solitary solid nodule measuring 6-8 mm, obtain follow-up CT at 6-12 months and again at 18-24 months. In patients with malignancy risk factors, a more intensive schedule of CT at 3-6 months, 9-12 months, and 24 months has been suggested.[23]

For an incidental solid nodule larger than 8 mm, do not default to prolonged surveillance. At approximately 3 months, choose repeat CT, FDG-PET/CT, or tissue sampling based on pretest probability, nodule morphology, patient fitness for curative treatment, and whether a tissue diagnosis will alter management.[8][19][23]
- Multiple incidental solid nodules smaller than 6 mm generally require no routine follow-up in low-risk patients; a 12-month CT is optional in high-risk patients.[23]
- For multiple solid nodules with at least one nodule 6-8 mm, obtain CT at 3-6 months, then consider CT at 18-24 months.[23]
- For multiple solid nodules with at least one nodule larger than 8 mm, obtain CT at 3-6 months and consider CT at 18-24 months; base escalation on the most suspicious lesion rather than the largest lesion alone.[23]

### When a solid nodule exceeds 8 mm

Estimate clinical probability of malignancy before PET/CT or biopsy. ACCP guidance supports PET/CT when clinical cancer risk is 5%-65%; PET interpretation is probability-dependent, with false-negative results more consequential in high-risk patients and false-positive results more problematic in low-risk patients.[2][4]

Proceed toward surgical diagnosis or excision rather than relying on a negative or equivocal noninvasive test when pretest probability is high and the patient is an operative candidate. ACCP-based summaries divide 8-30 mm solid nodules into low-, moderate-, and high-probability groups: low probability permits serial low-dose CT, moderate probability permits PET or serial CT, and high probability favors surgical diagnosis by biopsy or excision.[23]

Use nonsurgical biopsy when pathology is needed before treatment or when surgery is not an appropriate direct option. A nondiagnostic biopsy does not exclude cancer unless the specimen establishes a specific benign diagnosis; unresolved nodules may still require surgical resection.[2][24]
- Low pretest probability for an 8-30 mm solid nodule: low-dose CT at 3-6, 9-12, and 18-24 months is an option.[23]
- Moderate pretest probability: obtain PET/CT or use serial CT surveillance when the expected test result will change management.[23]
- High pretest probability: refer for surgical diagnostic evaluation when the patient is a candidate for definitive resection.[23][24]

*Incidental solid pulmonary nodule follow-up thresholds.[19][23]*

| Nodule pattern and size | Low-risk patient | Higher-risk patient or escalation condition |
| --- | --- | --- |
| Single solid nodule <6 mm | No routine follow-up.[23] | Optional CT at 12 months.[23] |
| Single solid nodule 6-8 mm | CT at 6-12 months; consider CT at 18-24 months.[23] | CT at 6-12 months and 18-24 months; some ACCP-based schedules use 3-6, 9-12, and 24 months with risk factors.[23] |
| Single solid nodule >8 mm | At about 3 months, consider CT, PET/CT, or tissue sampling after probability assessment.[19][23] | Use PET/CT for estimated clinical risk 5%-65%; high probability and operability favor surgical diagnosis.[2][23] |
| Multiple solid nodules with largest 6-8 mm | CT at 3-6 months; consider CT at 18-24 months.[23] | CT at 3-6 months and 18-24 months.[23] |
| Multiple solid nodules with largest >8 mm | CT at 3-6 months; consider CT at 18-24 months.[23] | CT at 3-6 months and 18-24 months; escalate based on the most suspicious nodule.[23] |

## Confirm persistence before committing to long-term subsolid surveillance

Pure ground-glass and part-solid nodules require separate thresholds from solid nodules.

Classify a subsolid nodule as pure ground glass or part solid on thin-section CT before setting the interval. The Fleischner subsolid guidance was developed separately because these nodules have more variable management and are linked to the peripheral adenocarcinoma spectrum.[16][18][20]

For a pure ground-glass nodule smaller than 6 mm, no routine follow-up is recommended. For a pure ground-glass nodule 6 mm or larger, obtain CT at 6-12 months to confirm persistence, then repeat CT every 2 years until 5 years if it persists.[23]

For a part-solid nodule 6 mm or larger, obtain CT at 3-6 months to confirm persistence. If persistent and the solid component remains smaller than 6 mm, perform annual CT for 5 years; a growing solid component or a solid component 6 mm or larger should prompt diagnostic evaluation rather than continued routine surveillance.[23]
- For multiple subsolid nodules smaller than 6 mm, obtain CT at 3-6 months; if stable, consider CT at 2 and 4 years.[23]
- For multiple subsolid nodules with at least one nodule 6 mm or larger, obtain CT at 3-6 months and manage according to the most suspicious lesion.[23]
- Do not treat a subsolid lesion as stable solely because a short interval CT is unchanged; persistent lesions are followed longer than solid nodules under Fleischner-based schedules.[23]

### Features that override a routine surveillance plan

A newly enlarging nodule, increasing solid component, or development of suspicious morphology should move the patient from surveillance to PET/CT, biopsy, or surgical evaluation according to lesion size, probability of malignancy, and treatment candidacy. Growth is strongly associated with malignancy, although slow-growing subsolid lesions may require prolonged observation to establish behavior.[9][23]

Use serial volumetric assessment when available and technically consistent. One volume-doubling time corresponds to an approximately 26% increase in diameter; most lung cancers have volume-doubling times up to 400 days, while volume-doubling time below 100 days is associated with the highest malignancy risk.[9]

*Fleischner-based follow-up for incidental subsolid nodules.[23]*

| Nodule type | Size threshold | Follow-up action |
| --- | --- | --- |
| Single pure ground-glass | <6 mm | No routine follow-up.[23] |
| Single pure ground-glass | ≥6 mm | CT at 6-12 months to confirm persistence, then every 2 years until 5 years.[23] |
| Single part-solid | <6 mm | No routine follow-up.[23] |
| Single part-solid | ≥6 mm with solid component <6 mm after persistence confirmed | CT at 3-6 months, then annual CT for 5 years.[23] |
| Single part-solid | Persistent with growing solid component or solid component ≥6 mm | Diagnostic evaluation rather than routine surveillance.[23] |

## Use Lung-RADS intervals for nodules found in screening programs

Lung-RADS is a screening reporting system, not an incidental-nodule surveillance schedule.

For Lung-RADS category 1 or 2 findings, continue annual low-dose CT screening. Category 3 findings require repeat low-dose CT at 6 months. These category-specific intervals should replace ad hoc application of incidental-nodule schedules in a screening program.[23]

For Lung-RADS category 4A, obtain low-dose CT at 3 months or PET/CT when the solid component exceeds 8 mm. For categories 4B and 4X, proceed with diagnostic chest CT with or without contrast, PET/CT, biopsy, or repeat low-dose CT at 1 month according to the imaging finding and probability of malignancy.[23]

A new nodule can carry different implications than a baseline finding. Screening algorithms therefore incorporate baseline versus interval-detected status rather than relying solely on an absolute diameter threshold.[1]
- Classify category 0 only after obtaining comparison with prior complete lung imaging when available.[23]
- Use PET/CT selectively for screening-detected lesions with a solid component larger than 8 mm; PET/CT does not replace diagnostic evaluation when clinical and imaging suspicion remain high.[4][23]
- For category 4B or 4X, arrange diagnostic workup rather than simply returning the patient to annual screening.[23]

*Lung-RADS follow-up intervals for screening-detected nodules.[23]*

| Lung-RADS category | Recommended next step |
| --- | --- |
| 0 | Compare with prior complete lung imaging before final classification.[23] |
| 1 or 2 | Continue annual low-dose CT.[23] |
| 3 | Low-dose CT at 6 months.[23] |
| 4A | Low-dose CT at 3 months or PET/CT if the solid component is >8 mm.[23] |
| 4B or 4X | Diagnostic chest CT with or without contrast, PET/CT, biopsy, or repeat low-dose CT at 1 month.[23] |

## Use probability, growth, and treatment candidacy to select PET/CT, biopsy, or resection

The purpose of follow-up is to avoid both delayed cancer diagnosis and unnecessary invasive testing.

For nodules larger than 8 mm or otherwise suspicious lesions, calculate or explicitly estimate pretest malignancy probability before choosing PET/CT, nonsurgical biopsy, or surgery. The Brock model incorporates age, sex, family history, emphysema, nodule size, nodule type, upper-lobe location, spiculation, and nodule count; risk models are intended to reduce false-positive diagnostic pathways.[11][12]

A BTS-style pathway illustrates actionable risk strata: for nodules larger than 8 mm or 300 mm3, calculate Brock risk; risk below 10% supports CT surveillance, while risk of 10% or greater prompts PET/CT and post-PET Herder reassessment. Herder risk below 10% supports surveillance, risk above 70% supports excision or nonsurgical treatment, and 10%-70% requires individualized selection among image-guided biopsy, surveillance, and excisional biopsy.[21][22]

Interpret PET/CT in the context of pretest probability rather than as a binary exclusion test. High-risk patients are vulnerable to harmful false reassurance from a false-negative PET/CT, while low-risk patients are vulnerable to unnecessary procedures after false-positive uptake.[4]
- Favor CT surveillance when the probability of malignancy is low and the lesion has no concerning interval growth.[4][21][23]
- Obtain tissue when diagnosis will change treatment selection, when direct resection is not appropriate, or when a specific benign process is plausible and can be established histologically.[2][24]
- Refer for surgical diagnostic evaluation when malignancy probability is high, the patient is operable, and noninvasive testing would not safely reduce uncertainty.[23][24]
- Assess fitness and patient preferences before invasive testing because guideline-based management explicitly weighs surveillance, nonsurgical biopsy, and surgical resection against their respective harms.[8][21]

*Risk-based escalation for a suspicious pulmonary nodule.[2][4][21][22][23]*

| Risk or finding | Test or management step | How the result changes action |
| --- | --- | --- |
| Low malignancy probability; no documented growth | CT surveillance at the morphology- and size-specific interval.[21][23] | Continue surveillance unless growth, new solid component, or suspicious morphology develops.[9][23] |
| Estimated clinical malignancy risk 5%-65% | FDG-PET/CT is supported by ACCP guidance.[2] | Integrate PET result with pretest probability; do not treat a negative PET/CT as definitive in a high-risk nodule.[4] |
| Brock risk ≥10% in BTS-style pathway | Obtain PET/CT and reassess risk with the Herder model.[21][22] | Herder risk <10% supports surveillance; 10%-70% permits biopsy, surveillance, or excision; >70% supports excision or nonsurgical treatment.[21][22] |
| High malignancy probability and surgical candidacy | Surgical diagnostic biopsy or excision.[23][24] | Avoid delaying definitive diagnosis with low-yield sequential testing when management would remain surgical.[24] |

## References
1. Pulmonary nodules and CT screening: the past, present and future — thorax.bmj.com — https://thorax.bmj.com/content/thoraxjnl/early/2016/02/26/thoraxjnl-2015-208107.full.pdf
2. Biopsy decision for intermediate–high-risk lung nodules is ... — bmjopenrespres.bmj.com — https://bmjopenrespres.bmj.com/content/12/1/e002553
3. Pulmonary nodules and CT screening: the past, present and future | Thorax — thorax.bmj.com — https://thorax.bmj.com/content/71/4/367
4. British Thoracic Society guidelines for the investigation and ... - Thorax — thorax.bmj.com — https://thorax.bmj.com/content/70/Suppl_2/ii1
5. Fleischner Society Guideline Recommendations for Incidentally Detected Pulmonary Nodules and the Probability of Lung Cancer — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1546144022005646
6. Creating an Incidental Pulmonary Nodule Safety-Net Program — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0012369221000337
7. Guidelines for the Evaluation of Pulmonary Nodules ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1546144020311194
8. Evaluation of Individuals With Pulmonary Nodules: When Is It Lung Cancer?: Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0012369213602913
9. Lung nodules : Annals of Thoracic Medicine — journals.lww.com — https://journals.lww.com/aotm/fulltext/2019/14040/lung_nodules__a_comprehensive_review_on_current.2.aspx
10. Calcified post-tuberculosis nodule at an unusual site : Journal of Clinical and Scientific Research — journals.lww.com — https://journals.lww.com/jcsr/fulltext/2023/12001/calcified_post_tuberculosis_nodule_at_an_unusual.17.aspx
11. Comparison of the Brock model and LU-RADS in... : Indian Journal of Cancer — journals.lww.com — https://journals.lww.com/indianjcancer/fulltext/2025/04000/comparison_of_the_brock_model_and_lu_rads_in.3.aspx
12. Lung cancer risk prediction models based on pulmonary nodules: A ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/1759-7714.14333
13. Malignancy risk stratification for solitary pulmonary nodule: A clinical ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/jebm.12476
14. Development and Internal Validation of a Patient‐Level Diagnostic ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/1759-7714.70358
15. Using a risk model for probability of cancer in pulmonary nodules — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13991
16. Recommendations for the Management of Subsolid Pulmonary Nodules Detected at CT: A Statement from the Fleischner Society — pubs.rsna.org — https://pubs.rsna.org/doi/10.1148/radiol.12120628
17. Updated Fleischner Society Guidelines for Managing Incidental Pulmonary Nodules: Common Questions and Challenging ScenariosRadioGraphics — pubs.rsna.org — https://pubs.rsna.org/doi/abs/10.1148/rg.2018180017
18. Recommendations for the management of subsolid pulmonary nodules detected at CT: a statement from the Fleischner Society - PubMed — www.ncbi.nlm.nih.gov — http://www.ncbi.nlm.nih.gov/pubmed/23070270
19. Guidelines for Management of Incidental Pulmonary Nodules Detected on                    CT Images: From the Fleischner Society 2017 — pubs.rsna.org — https://pubs.rsna.org/doi/full/10.1148/radiol.2017161659
20. Recommendations for the Management of Subsolid Pulmonary Nodules Detected at CT: A Statement from the Fleischner SocietyRadiology — pubs.rsna.org — http://pubs.rsna.org/doi/pdf/10.1148/radiol.12120628
21. 2 The diagnostic tests | EarlyCDT Lung for assessing risk of lung cancer in solid lung nodules | CLONE OF DG46: EarlyCDT Lung for assessing risk of lung cancer in solid lung nodules | Consultations | NICE — www.nice.org.uk — https://www.nice.org.uk/consultations/1128/1/the-diagnostic-tests
22. [PDF] EarlyCDT Lung for assessing risk of lung cancer in solid lung nodules — www.nice.org.uk — https://www.nice.org.uk/guidance/HTG611/documents/514
23. Solitary Pulmonary Nodule - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK556143
24. [Solitary pulmonary nodule on CT - observation or surgical resection?] - PubMed — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pubmed/22753287

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.